IGY 110
Alternative Names: Anti-coronavirus IgY antibody - IGY Life Sciences; IgY-110Latest Information Update: 28 Jul 2024
At a glance
- Originator IGY Life Sciences
- Class Antivirals; Polyclonal antibodies
- Mechanism of Action Immunomodulators; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in Canada (Intranasal, Spray)
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in Canada (PO, Capsule)
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Canada (Intranasal, Spray)